XOMA Royalty (NASDAQ:XOMA) Stock Passes Above 200 Day Moving Average – Here’s Why

XOMA Royalty Corporation (NASDAQ:XOMA)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $30.13 and traded as high as $30.50. XOMA Royalty shares last traded at $30.25, with a volume of 76,544 shares.

Analyst Ratings Changes

Several research firms have weighed in on XOMA. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. UBS Group set a $76.00 target price on shares of XOMA Royalty in a research report on Tuesday, December 9th. Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Finally, Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a report on Friday, December 12th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $61.60.

XOMA Royalty Stock Up 0.3%

The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15. The business’s fifty day moving average price is $26.39 and its two-hundred day moving average price is $30.13. The firm has a market cap of $360.16 million, a P/E ratio of 20.72 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.16. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. The firm had revenue of $13.76 million during the quarter, compared to analysts’ expectations of $11.13 million. As a group, equities research analysts anticipate that XOMA Royalty Corporation will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XOMA. Russell Investments Group Ltd. boosted its holdings in XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of XOMA Royalty during the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC boosted its position in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,523 shares during the period. BNP Paribas Financial Markets boosted its position in shares of XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,346 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.